17 results on '"Bewersdorf JP"'
Search Results
2. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia.
3. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
4. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia.
5. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
6. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
7. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
8. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States.
9. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.
10. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
11. Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?
12. Clinical outcomes and characteristics of patients with TP53 -mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.
13. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
14. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
15. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study † .
16. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.
17. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.